Quick Takeaways
- Commodore Capital LP filed SCHEDULE 13G/A for Terns Pharmaceuticals, Inc. Common Stock, $0.0001 par value per share (TERN).
- Disclosed ownership: 6.5%.
- Date of event: 30 Sep 2025.
Commodore Capital LP - 30 Sep 2025 SCHEDULE 13G/A Report for Terns Pharmaceuticals, Inc. Common Stock, $0.0001 par value per share (TERN)
- Filing Manager
- Commodore Capital LP
- Reporting Manager
- Commodore Capital LP
- Symbol
- TERN
- Shares outstanding
- 87,692,308 shares
- Disclosed Ownership
- 5,700,000 shares
- Ownership
- 6.5%
- Form type
- SCHEDULE 13G/A
- Filing time
- 14 Nov 2025, 16:51:37 UTC
- Date of event
- 30 Sep 2025
- Previous filing
- 16 Sep 2025
- Next filing
- 17 Feb 2026
- SEC
- View on sec.gov
Quoteable Key Fact
"Commodore Capital LP disclosed 6.5% ownership in Terns Pharmaceuticals, Inc. Common Stock, $0.0001 par value per share (TERN) on 30 Sep 2025."
What Changed
- Previous schedule filing date: 16 Sep 2025.
- Current filing was accepted on 14 Nov 2025, 16:51.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Official SEC Source
Backed by Schedule 13D/13G
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
See Original FilingReporting Managers (4)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Commodore Capital LP | 6.5% | 5,700,000 | 0 | 5,700,000 | Michael Kramarz | Managing Partner | |
| Commodore Capital Master LP | 6.5% | 5,700,000 | 0 | 5,700,000 | Michael Kramarz | Managing Partner | |
| Robert Egen Atkinson | 6.5% | 5,700,000 | 0 | 5,700,000 | Robert Egen Atkinson | Authorized Signatory | |
| Michael Kramarz | 6.5% | 5,700,000 | 0 | 5,700,000 | Michael Kramarz | Authorized Signatory |